DUBLIN, Ireland, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc AVDL, a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that members of the Avadel management team will present at both the Stifel Virtual Healthcare Conference and the Jefferies Virtual London Healthcare Conference that are being held in November 2020.
| Event: | Stifel 2020 Virtual Healthcare Conference |
| Date: | Monday, November 16 |
| Time: | 9:20 a.m. ET |
| Webcast: | A webcast will be available at the "Investors" section of the Company's website at www.avadel.com. A replay of the webcasts will be available on Avadel's website for 90 days following the presentation. |
| Event: | Jefferies Virtual London Healthcare Conference |
| Date: | Wednesday, Nov. 18th |
| Time: | 6:45 p.m. GMT (1:45 p.m. ET) |
| Webcast: | A webcast will be available at the "Investors" section of the Company's website at www.avadel.com. A replay of the webcasts will be available on Avadel's website for 90 days following the presentation. |
About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc AVDL is an emerging biopharmaceutical company. The Company's primary focus is the development and FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.
Contacts:
Tom McHugh
Chief Financial Officer
Phone: (636) 449-1843
Email: tmchugh@avadel.com
Tim McCarthy
LifeSci Advisors, LLC
Phone: (212) 915.2564
Email: tim@lifesciadvisors.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
